Versiti to Coordinate NIH Trials of Blood Thinners to Improve Care for COVID-19 Patients at Risk for Blood Clots - PRNewswire

-

MILWAUKEE, April 29, 2021 /PRNewswire/ -- Versiti has been granted three multi-center research contracts to coordinate nationwide clinical trials aimed at establishing optimal treatment plans for preventing blood clots in people with COVID-19. The contracts were awarded to Versiti by the University of Pittsburgh with funding by National Institutes of Health (NIH).

Results of the collaborative effort of three international trials have already led to findings that may change the standard of care in hospitalized patients with COVID-19. Interim results from the trials showed that full-dose anticoagulation (blood thinner) treatments given to hospitalized patients outside of the intensive care unit were shown to reduce how many people required vital organ support—such as the need for ventilation.  

Early in the pandemic, hospitals globally observed the potential of increased rate of blood clots among hospitalized COVID-19 patients. It was unclear at that time whether providing patients increased doses of blood thinners would be safe and effectively decrease the progression of COVID-19 illness.

Versiti Medical Director of Hematology, BRI Associate Investigator, and Medical Director of the Clinical Trials and Research Office Dr. Lisa Baumann Kreuziger MD, MS, is named as the Research Director to coordinate one of networks involved in the trials. 

"Having the opportunity to coordinate and participate in research that is already being put into practice to help people suffering from COVID-19 is an honor," said Dr. Baumann Kreuziger. "Research conducted at this incredible pace with an unprecedented level of multi-center coordination across disciplines is not only making a positive impact on COVID-19 patient care, it is setting the tone for future research projects." 

Dr. Baumann Kreuziger is co-founder of the Venous thromboEmbolism Network U.S. (VENUS), working with other institutions across the country to perform clinical research about blood clots.

These research projects are known as Accelerating COVID-19 Therapeutic Interventions and Vaccines-4 (ACTIV-4) Antithrombotics, which is managed by the NIH and evaluates the effectiveness of anti-platelets (e.g., aspirin or Plavix), anti-coagulants (e.g., Heparin) in progression of COVID-19 and prevention of blood clots. ACTIV brings together multiple partners from government, industry, academia and non-profit organizations. 

Versiti, as the coordinating center for VENUS, is organizing three ACTIV-4 studies:

  • ACTIV-4A involves patients hospitalized for COVID-19
  • ACTIV-4B involves patients who test positive for COVID-19 but are not hospitalized
  • ACTIV-4C involves patients with COVID-19 who are going home from the hospital

Funding from the NIH totals approximately $5 million to support Versiti's and the clinical trial sites' efforts to perform the multi-center trials.

Versiti is also participating as a coordinating center and trial site for the Rapid COVID COAG Study and is now the fifth-highest enrolling site in the world.

The Rapid COVID COAG Study is led by Dr. Michelle Sholzberg and Dr. Peter Juni (both of St. Michael's Hospital, Toronto, Canada) and Dr. Mary Cushman (University of Vermont). Dr. Lisa Baumann Kreuziger is a member of the RAPID trial's steering committee. They also are involved with the protocol development for the ACTIV-4 trials: Dr. Cushman on ACTIV 4A; Dr. Sholzberg on 4B; and Dr. Baumann Kreuziger on 4C.

About Versiti
Versiti, a national leader in blood health innovation, was formed with the mission to improve the health of patients and enable the success of our health care partners nationally. We provide innovative, value-added solutions in the fields of transfusion medicine, transplantation, and blood-related diseases to meet the needs of each of our customers. The collective efforts across Versiti result in improved patient outcomes, expanded access to care and cost efficiencies for health care systems nationwide. For more information, visit versiti.org.

SOURCE Versiti

Related Links

http://www.Versiti.org

Comments

Post a Comment

Popular posts from this blog

Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

-
Image
Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and...
Read more

Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

-
Image
3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t...
Read more

Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

-
Image
hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n...
Read more